Novartis NVS, the Swiss pharmaceutical giant, traded at $159.99 Monday after pelacarsen flopped in a pivotal Phase 3 cardiovascular trial. Reuters estimated that roughly CHF4.9 billion evaporated from the company’s market value, while its Zurich-listed shares fell 1.9%. The market’s message was brutal: another potential blockbuster just disappeared from the pipeline.

The company reported that pelacarsen lowered lipoprotein(a) but failed where it mattered most. The drug did not significantly reduce cardiovascular deaths, heart attacks, strokes or urgent coronary procedures versus placebo. Lp(a)HORIZON enrolled 8,323 patients, leaving little room to explain away the miss. Detailed results will come later, but investors have already delivered their verdict.

Novartis remains a cash machine, with second-quarter sales of $14.41 billion and $5.56 billion of free cash flow. This failure does not drain cash today—it deletes growth investors expected tomorrow. The stock’s $159.99 price also sits 22.53% above its GF Value estimate of $130.57, showing that plenty of pipeline optimism remains baked into the valuation. Now the pressure shifts to fourth-quarter data for del-desiran, acquired through the $12 billion Avidity deal. One major failure has turned the next clinical readout into a must-win event.